Eyepoint Pharmaceuticals (NASDAQ:EYPT) Posts Earnings Results, Misses Estimates By $0.14 EPS

Eyepoint Pharmaceuticals (NASDAQ:EYPT) announced its quarterly earnings data on Thursday. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.14), FiscalAI reports. The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.23 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%.

Here are the key takeaways from Eyepoint Pharmaceuticals’ conference call:

• Both Phase III wet AMD trials missed their primary endpoint in the full analysis population. EyePoint highlighted DURAVYU’s biological activity, reduced treatment burden, and safety, but is discontinuing the wet AMD program while it reviews whether any patient subgroup could support a future path.
• EyePoint ended September with about $118 million in cash and expects to fund operations into late Q3 2027, while COMO and CAPRI results are expected in early Q4 2027. Management says it is evaluating additional cost reductions, financing, and business-development options to preserve runway and reach the readouts.
• EyePoint is concentrating its clinical efforts on DME, citing the disease’s distinct biology and Phase II VERONA results, including vision improvement and fewer supplemental injections with DURAVYU. The company expects simultaneous top-line results from the two Phase III trials, which enrolled more than 550 patients, in early Q4 2027; efficacy in these pivotal studies remains unproven.
• After the wet AMD results, EyePoint amended DME rescue-injection criteria so patients may receive supplemental treatment after a greater-than-five-letter BCVA decline from baseline alongside a CST increase of at least 50 microns. The company says the change is intended to help preserve vision and protect the trials’ non-inferiority objective; it is not planning a futility analysis.
• EyePoint plans to reduce its workforce by about 53% and says the move will generate approximately $30 million in annualized savings once fully implemented, aligning spending with the DME program.

Eyepoint Pharmaceuticals Price Performance

Shares of Eyepoint Pharmaceuticals stock traded down $0.04 on Thursday, hitting $0.32. 5,617,256 shares of the company’s stock traded hands, compared to its average volume of 3,689,083. The firm’s 50-day moving average price is $2.50 and its two-hundred day moving average price is $10.40. The stock has a market capitalization of $27.67 million, a PE ratio of -0.09 and a beta of 1.84. Eyepoint Pharmaceuticals has a one year low of $0.31 and a one year high of $19.11.

Wall Street Analyst Weigh In

EYPT has been the topic of several analyst reports. Weiss Ratings upgraded Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 1st. JPMorgan Chase & Co. downgraded Eyepoint Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Tuesday, October 20th. Citigroup decreased their price target on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, August 18th. Stifel Nicolaus initiated coverage on Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Cantor Fitzgerald lowered Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, August 17th. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $21.85.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.